IntelGenx (OTCQX:IGXT; TSXV:IGX) submitted a clinical trial application to Health Canada for approval to initiate a Phase 2a proof-of-concept study with montelukast in mild-to-moderate Alzheimer's disease (AD).Read More
Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.Read More
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.Read More
ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.Read More
ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
“ProMIS will apply its proprietary computational algorithms, supplemented by other methods pioneered by ProMIS scientists, to identify specific therapeutic targets on misfolded TDP43,” SCO, Dr. Neil Cashman, said in a statement.Read More
ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the development of Alzheimer’s disease (AD).
“With multiple product candidates in our Ab program progressing to final validation and selection for drug development, we are focusing our science team and discovery processes on the other half of the root cause – tau prions.” SCO, Dr. Neil Cashman, explained in a statement.Read More
Anavex Life Sciences (NASDAQ:AVXL) has reported positive data for ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorder in Mount Snow, VT.
Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism.Read More